Inactive Instrument

All News Bio-Path Holdings Inc OTC Bulletin Board

Equities

BPTH

US09057N1028

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

14/06	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	CI
05/06	Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bio-Path Holdings Provides Clinical Update and Expansion Plans	08/07	AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress	14/06	AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	14/06	CI
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	06/06	AQ
Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	05/06	CI
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24	05/06	NE
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	04/06	AQ
Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding	04/06	CI
Sector Update: Health Care Stocks Gain Late Afternoon	04/06	MT
Top Midday Gainers	03/06	MT
Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May	03/06	MT
Investors Await Key Manufacturing Data as US Futures Nudge Higher in Monday's Premarket Session	03/06	MT
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting	03/06	AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At American Society of Clinical Oncology Annual Meeting	03/06	CI
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress	24/05	AQ
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting	24/05	AQ
Transcript : Bio-Path Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024	15/05
Bio-Path: Q1 Earnings Snapshot	15/05	AQ
Bio-Path Holdings Reports First Quarter 2024 Financial Results	15/05	AQ
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Bio-Path Holdings Inc OTC Bulletin Board

Equities

BPTH

US09057N1028

All News

Filters